Our translational research focuses on oncolytic measles viruses for cancer therapy. A Phase I/II clinical trial of immunovirotherapy for advanced gastrointestinal tumors is currently in preparation.
- Proof of concept that oncolytic Measles vectors encoding bispecific T cell engagers (BiTEs) are effective against solid tumors (Speck and Heidbuechel et al., Clinical Cancer Research 2018)
- Oncolytic Measles vectors enconding IL-12 achieve 90 % durable complete remissions in preclinical tumor models (Veinalde et al., OncoImmunology 2017)
- Development of oncolytic Measles virus vectors encoding anti-CTLA-4 and anti-PD-L1 to enhance immunovirotherapy and reduce side effects of checkpoint blockade (Engeland et al., Molecular Therapy 2014)
- Demonstration that oncolytic Measles virus can induce tumor-specific immunity, resulting in a protective tumor vaccination effect (Grossardt et al., Human Gene Therapy 2013)
- Post-entry targeting of measles virus vectors via insertion of microRNA to increase safety of oncolytic agents (Leber et al. Molecular Therapy 2011; Baertsch et al., Cancer Gene Therapy 2014)
- Establishment of targeted chemovirotherapy against lymphoma (Ungerechts et al.,Cancer Research 2007; Ungerechts et al., Gene Therapy 2010), pancreatic cancer (Bossow et al., Cancer Gene Therapy 2011), head and neck cancer (Zaoui et al., Gene Therapy 2011) and malignant melanoma (Kaufmann et al., J Invest Dermatol 2013)